Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Candida auris can survive antifungal pressure by duplicating resistance-linked DNA, including whole chromosomes. The finding does not mean the yeast routinely copies every nucleotide in its genome. Instead, a 2026 Nature Communications study shows that segmental duplications and extra, centromere-containing chromosomes can increase drug-resistance gene dosage and alter how cells respond to treatment.
What the 2026 study found
Researchers analyzed 79 clinical isolates from India’s South Asian clade 1, collected between 2014 and 2021. Sixty of the isolates came from blood. The team combined whole-genome sequencing, copy-number analysis, long-read sequencing, electrophoretic karyotyping and mutation-accumulation experiments to identify structural changes that ordinary point-mutation screens can miss.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Medical Microbiology | $70.57 | Buy on Amazon |
| 2 |
|
Medical Microbiology | $48.58 | Buy on Amazon |
| 3 |
|
Clinical Microbiology Made Ridiculously Simple: Spiral Bound Color Edition | $54.95 | Buy on Amazon |
| 4 |
|
Textbook of Diagnostic Microbiology | $114.97 | Buy on Amazon |
| 5 |
|
Microbiology: The Human Experience | $173.88 | Buy on Amazon |
As an Amazon Associate I earn from qualifying purchases.
The central mechanism was segmental duplication: a stretch of DNA is copied, creating extra gene copies. In some isolates, the duplicated segment included a centromere and persisted as a separate supernumerary chromosome. These extra chromosomes can change the amount of resistance-related protein a cell produces without altering the gene’s sequence.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Aswathy Narayanan and co-authors describe segmental duplication as a major non-mutational driver of antifungal resistance and argue that structural variation should be included in resistance surveillance and clinical susceptibility testing. The article appears in Nature Communications, volume 17, article 8544.
#1 Best Overall
Which DNA changes affect which drugs?
ERG11 duplications and azole resistance
Small duplications around ERG11 can raise resistance to azole drugs. ERG11 encodes the azole target enzyme; extra copies increase gene dosage, helping the cell maintain target activity despite the drug. The duplications were often found alongside resistance-associated ERG11 point mutations, so structural and single-nucleotide changes can reinforce one another rather than acting as alternative explanations.
Chromosome 1 and reduced caspofungin susceptibility
Large duplications that include the centromere of chromosome 1 can remain as supernumerary chromosomes. In the clinical isolates, these structures were associated with paradoxical growth and reduced susceptibility to the echinocandin caspofungin. A cell may therefore carry an extra chromosome while retaining its normal chromosome 1, increasing the dosage of multiple genes at once.
Rank #2
The Eagle effect can hide the phenotype
The study discusses the Eagle effect: growth appears to stop at a lower drug concentration but reappears at higher concentrations. Standard minimum inhibitory concentration (MIC) testing and conventional breakpoints may record the low-concentration inhibition while overlooking this supra-MIC growth pattern. A result that looks susceptible on a routine panel can therefore fail to describe the organism’s full behavior under drug exposure.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallCrashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteClinical isolates versus laboratory evolution
The Indian isolate collection provides patient-derived evidence, while an earlier 2022 mBio experiment shows how quickly a related process can emerge under controlled selection.
| Evidence | Starting material and exposure | Structural route | Drug phenotype | What happened after drug-free passage |
|---|---|---|---|---|
| 2026 clinical study | 79 South Asian clade-1 isolates from India, collected 2014–2021; 60 were blood isolates | ERG11-region duplications and chromosome-level duplications, including centromere-containing chromosome 1 structures | Stronger azole resistance; reduced caspofungin susceptibility and paradoxical growth in associated isolates | Not established by the cohort analysis; structural variants may be transient or reversible |
| 2022 laboratory evolution | One susceptible clade-2 isolate exposed to fluconazole for 100 generations | Two resistant lines acquired centromere-containing chromosome 5 duplications measuring 638 kb and 675 kb | Fluconazole resistance | Loss of the extra chromosomes during drug-free passage completely restored fluconazole susceptibility |
| 2022 laboratory evolution, third line | The same experimental starting strain and selection | Non-aneuploid overexpression of a drug-efflux pump | Fluconazole resistance through altered gene expression rather than an extra chromosome | Not stated for this line |
The laboratory result is especially important because it demonstrates reversibility: removing an acquired extra chromosome removed the resistant phenotype in those lines. It also shows that the same starting strain can reach resistance through different routes, including efflux-pump overexpression rather than aneuploidy.
Why “copies its entire genome” is an oversimplification
The headline phrase is useful shorthand but biologically imprecise. The evidence supports recurrent duplication of resistance-relevant regions and, in some cases, an entire chromosome. It does not show routine copying of every chromosome or every nucleotide in the genome.
Rank #4
These changes are forms of copy-number variation. A duplicated segment can be embedded in a chromosome, while a centromere-containing duplication can segregate as an additional chromosome. Because the extra DNA may later be lost, the genotype detected in one sample can differ from the phenotype expressed after further growth or treatment.
How this changes resistance testing
Traditional testing emphasizes MIC values and point mutations such as changes in FKS1 or ERG11. The findings indicate that laboratories may also need to look for:
Best Value
- Extra copies of ERG11 and other resistance-linked regions.
- Large duplications that include centromeres and behave as supernumerary chromosomes.
- Structural variants that occur together with FKS1 or ERG11 mutations.
- Paradoxical growth at drug concentrations above the level that initially inhibits growth.
- Phenotypic changes that could follow loss of an unstable or reversible extra chromosome.
Detecting these features may require copy-number analysis, long-read sequencing or chromosome-level methods in addition to routine short-read sequencing and MIC panels. The study identifies a surveillance and diagnostic need; it does not prescribe a new treatment regimen for patients.
What the evidence does—and does not—establish
Supported conclusions
- Structural duplication is a real resistance route. It can increase gene dosage without a conventional point mutation.
- Different drugs can be affected by different structures. ERG11 copy gain is linked to azole resistance, while chromosome-1 structures are linked to caspofungin-associated phenotypes.
- Resistance mechanisms can combine. Copy-number changes may coexist with FKS1 or ERG11 mutations.
- Some chromosome changes are reversible. The 2022 experiment recovered fluconazole susceptibility after the extra chromosomes were lost.
Important limits
- The 2026 clinical cohort is limited to South Asian clade-1 isolates from India. It does not prove that every C. auris lineage uses the same duplications.
- The clinical study explains mechanisms and testing implications, not a replacement therapy or patient-specific prescribing rule.
- A single isolate may not capture all phenotypes over time when structural variants are unstable or reversible.
- The 2022 chromosome-loss result came from laboratory-evolved lines, not a clinical treatment trial.
Why the finding matters
Candida auris can adapt through more than one genetic pathway. Point mutations remain important, but duplicated DNA can provide a rapid dosage increase, sometimes affecting several genes simultaneously. Because those changes may be missed by mutation-only surveillance and because paradoxical growth can confuse MIC interpretation, a complete resistance assessment needs both genotype and phenotype. The clinical evidence currently comes from a geographically and genetically defined group, so broader claims should wait for studies across additional clades and regions.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
